Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

Click for more information

0.00%

8.0¢ kazia therapeutics limited

TRXE-002-1 (Cantrixil) Toxicology, page-2

First 2 Last

stotes

4,218 Posts.

1128

16/04/16

09:17

Post #: 17519416

Originally posted by Ninja_Chook ↑

At long last the abstract for the Cantrixil Toxicology presentation is out.

No nasty surprises in it.

The conclusion says it all, "These data show that TRXE-002-1 has an acceptable toxicity profile in rats and dogs, and is without genotoxicity and cardiotoxicity at clinically relevant concentrations."

Here it is:

Column 1

1 Introduction: TRXE-002-1 is a low molecular weight super benzopyran molecule identified as having potent activity against many cancer phenotypes. It was identified from a library of analogues as being able to induce cell death in both chemoresistant CD44+/MyD88+ ovarian cancer stem cells (IC50 of ~ 50 nM) and chemosensitive CD44-/MyD88- ovarian cancer cells, and disrupt spheroid cultures formed from cancer stem cells. In vivo studies have confirmed efficacy in a rodent intra-peritoneal model of human ovarian cancer. Here we report on pre-clinical toxicology studies conducted on TRXE-002-1.Method: We conducted a full GLP dog CV study using a 4X4 Latin Square Crossover study design where we assessed telemetric ECG recordings from 4 male dogs post IP administration at doses up to 30 mg/kg. Thirty seconds of continuous ECG tracings were collected pre-dose (Baseline) and at 0.5, 1.5, 2.5, and, 24 hours after test article or vehicle administration. In addition, TRXE-002-1 was assessed in standard assays used to identify mutagenic potential using the bacterial reverse mutation assay. The potential for TRXE-002-1to induce micronuclei in the bone marrow of SPF Arc(S) Swiss mice was also investigated as a measure of clastogenicity. TRXE-002-1 toxicology was evaluated in MTD, and 28-day repeat dose GLP studies in rats and dogs.Results: TRXE-002-1 was found to have no effect on cardiac parameters of blood pressure and electrocardiography in dogs. TRXE-002-1 had no reverse mutagenic potential using the bacterial reverse mutation pre-incubation method ± S9 metabolic activation (Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, and the WP2 uvrA Escherichia coli strain). Similarly, TRX-E-002-1 was shown to be non-mutagenic using the gene mutation test at the TK locus in L5178Y mouse lymphoma cell culture with and without metabolic activation. High doses of TRXE-002-1 (200 and 400 mg/kg) caused a significant increase in incidence of micronuclei in male and female mice. Repeat intraperitoneal injection of TRXE-002-1 to male and female dogs and rats over 28 days was well tolerated. Adverse TRXE-002 1-related effects were limited to microscopic findings in the testes and epididymides for male rats and dogs at high doses. Macroscopic observations at necropsy were confined to sporadic distention of the cecum and colon and colon obstruction in rats only (high dose) with no observed gastrointestinal microscopic findings reported in either species. Other observations were mostly resolved after a 14-day recovery period, except microscopic findings in the testes from both species.Conclusion: These data show that TRXE-002-1 has an acceptable toxicity profile in rats and dogs, and is without genotoxicity and cardiotoxicity at clinically relevant concentrations. TRXE-002-1 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for ovarian cancer and a first-in-human clinical trial is planned for 2016.

http://www.abstractsonline.com/Plan...971&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267

Bring on the trials!

Expand

This has been a long time coming and I'm hoping now that this milestone has passed Novogen will step up on its shareholder communication and begin to once again, start telling the story to the market which GK so eloquently and succinctly was able to tell.

I have seen the shift in the NRT threads over the last few weeks, positive notes are in the air and we all feel it.

Last edited by stotes: 16/04/16

NRT Price at posting: 13.0¢ Sentiment: Buy Disclosure: Held

0 Great analysis

Top Stories

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

There are more pages in this discussion • 49 more messages in this thread...

First 2 Last

Add KZA (ASX) to my watchlist